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Abstract 
Background: The prevalence of abnormal cardiovascular magnetic resonance (CMR) findings in recovered corona-
virus disease 2019 (COVID-19) patients is unclear. This study aimed to investigate the prevalence of abnormal CMR 
findings in recovered COVID-19 patients.
Methods: A systematic literature search was performed to identify studies that report the prevalence of abnormal 
CMR findings in recovered COVID-19 patients. The number of patients with abnormal CMR findings and diagnosis of 
myocarditis on CMR (based on the Lake Louise criteria) and each abnormal CMR parameter were extracted. Subgroup 
analyses were performed according to patient characteristics (athletes vs. non-athletes and normal vs. undetermined 
cardiac enzyme levels). The pooled prevalence and 95% confidence interval (CI) of each CMR finding were calculated. 
Study heterogeneity was assessed, and meta-regression analysis was performed to investigate factors associated with 
heterogeneity.
Results: In total, 890 patients from 16 studies were included in the analysis. The pooled prevalence of one or more 
abnormal CMR findings in recovered COVID-19 patients was 46.4% (95% CI 43.2%–49.7%). The pooled prevalence 
of myocarditis and late gadolinium enhancement (LGE) was 14.0% (95% CI 11.6%–16.8%) and 20.5% (95% CI 17.7%–
23.6%), respectively. Further, heterogeneity was observed  (I2 > 50%, p < 0.1). In the subgroup analysis, the pooled 
prevalence of abnormal CMR findings and myocarditis was higher in non-athletes than in athletes (62.5% vs. 17.1% 
and 23.9% vs. 2.5%, respectively). Similarly, the pooled prevalence of abnormal CMR findings and LGE was higher in 
the undetermined than in the normal cardiac enzyme level subgroup (59.4% vs. 35.9% and 45.5% vs. 8.3%, respec-
tively). Being an athlete was a significant independent factor related to heterogeneity in multivariate meta-regression 
analysis (p < 0.05).
Conclusions: Nearly half of recovered COVID-19 patients exhibited one or more abnormal CMR findings. Athletes 
and patients with normal cardiac enzyme levels showed a lower prevalence of abnormal CMR findings than non-
athletes and patients with undetermined cardiac enzyme levels.
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Background
The spread of coronavirus disease 2019 (COVID-19) was 
rapid, and COVID-19 was quickly designated as a pan-
demic since the first identified case in December 2019 
in Wuhan, China [1]. As of July 7, 2021, more than 184 
million people have been diagnosed with COVID-19 and 
nearly 4 million have died of the infection [2]. Although 
COVID-19 is primarily a respiratory disease, cardio-
vascular complications have been reported [3, 4] and 
are associated with higher mortality and risk of severe 
COVID-19 [5, 6]. Cardiac involvement in COVID-19 can 
manifest as myocarditis, heart failure, acute coronary 
syndrome, or arrhythmias [4, 7]. Among these, myocar-
ditis has clinical significance because myocardial inflam-
mation can result in permanent myocardial damage and 
contribute to the development of arrhythmia or chronic 
heart failure [7, 8].
Cardiovascular magnetic resonance (CMR) is used to 
diagnose cardiovascular complications of COVID-19, 
such as acute myocarditis, using the recently updated 
Lake Louise criteria [9]. Individual reports and one sys-
tematic review of CMR findings in COVID-19 patients 
have been published to date; however, most focused on 
patients in the active disease stage [10]. Notably, recent 
data indicated that the prevalence of abnormal CMR 
findings, such as myocardial edema and late gadolinium 
enhancement (LGE), in recovered COVID-19 patients is 
substantial [11–22]; however, their prevalence is highly 
variable. Although the clinical significance of abnormal 
CMR findings in recovered COVID-19 patients is not 
yet fully understood, determining the prevalence of such 
findings in certain subgroups of patients would benefit 
clinical decision-making. For example, the presence of 
myocardial scars after myocarditis can lead to sudden 
cardiac death, especially in athletes. Consequently, the 
prevalence of abnormal CMR findings in athletes who 
have recovered from COVID-19 affects their return to 
play [23–25].
Therefore, the purpose of this study was to investigate 
the prevalence of abnormal CMR findings in recovered 
COVID-19 patients through meta-analysis.
Methods
Our methods followed the recommendations of the pre-
ferred reporting items for systematic reviews and meta-
analyses statement [26], and the study protocol was 
registered in the PROSPERO database (registration num-
ber: CRD42020225234).
Literature search
Two cardiothoracic radiologists with 5 and 8  years of 
experience, in performing meta-analyses designed the 
search strategy in consensus. Each individual inde-
pendently performed systematic searches of PubMed, 
EMBASE, the Cochrane library, SSRN, and MedRxiv/
BioRxiv on March 3, 2021, to identify studies published 
since 2020. The search terms are listed in Additional 
file 1: Appendix S1.
Study selection
Two investigators independently reviewed the retrieved 
articles. A flowchart summarizing the literature search 
process is shown in Fig. 1. To determine the study eligi-
bility, the full text of articles was evaluated for inclusion 
using the following criteria: (1) type of study, i.e., rand-
omized controlled studies, prospective or retrospec-
tive cohort studies, and case–control studies with more 
than 10 patients; (2) study population, i.e., patients who 
recovered from COVID-19 and underwent CMR after 
recovery; and (3) primary outcome, i.e., the prevalence 
of abnormal CMR findings. Abnormal CMR findings 
included the presence of ventricular systolic dysfunction 
on cine imaging, the presence of myocardial or pericar-
dial late gadolinium enhancement (LGE), abnormal sig-
nal intensity on T2-weighted (T2w) imaging, elevated 
native T1 or T2 values on the mapping sequence, a diag-
nosis of myocarditis based on the updated Lake Louise 
criteria, and the presence of pericardial effusion [9].
In contrast, a study was excluded if the study popula-
tion was restricted to COVID-19 patients with multisys-
tem inflammatory syndrome or reported CMR findings 
during the acute stage of COVID-19.
Data extraction
Two investigators independently extracted data with 
disagreements resolved by consensus. The extracted 
parameters included the following: (a) article infor-
mation and patient characteristics; (b) CMR protocol, 
i.e., CMR scanner type (1.5 or 3  T) and obtained CMR 
sequences including cine, parametric  mapping (T1 and 
T2), LGE, and T2w; and (c) CMR findings, i.e., the num-
ber of patients with normal and abnormal CMR findings, 
abnormal cine findings (ventricular systolic dysfunction), 
Trial registration The study protocol was registered in the PROSPERO database (registration number: 
CRD42020225234).
Keywords: Cardiac magnetic resonance imaging, Magnetic resonance imaging, Coronavirus disease 2019
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elevated parametric mapping (native T1 and T2) and 
extracellular volume (ECV) values, presence of LGE 
(myocardial or pericardial), myocardial segments with 
abnormal T2 or LGE areas, myocardial LGE patterns 
(non-ischemic, ischemic, or dual) that fulfilled the diag-
nostic criteria for myocarditis on CMR based on the Lake 
Louise criteria [9], and presence of pericardial effusion. 
LGE at the right ventricular (RV) insertion points in the 
interventricular septum was not considered to indicate 
LGE presence because it is a common non-specific find-
ing in athletes [27].
Subgroup analysis
Subgroups were stratified according to (a) whether a 
patient group was limited to athletes and (b) levels of car-
diac enzymes (troponin I or high-sensitivity troponin T) 
when CMR was performed. Studies wherein the cardiac 
enzyme data were not extractable were assigned to the 
“undetermined cardiac enzyme level” subgroup. An anal-
ysis of an “elevated cardiac enzyme level” subgroup could 
not be performed, because there were only seven patients 
in three studies who had elevated cardiac enzyme levels 
and extractable CMR findings [11, 28, 29].
Quality assessment
Two investigators independently performed quality 
assessments of the selected studies using the Newcastle–
Ottawa Quality Scale [30]: for each question within the 
Selection and Exposure/Outcome categories, the maxi-
mum score is 1, and for the Comparability category, the 
top score is 2. A study with a total score of 6 or higher 
was considered of “high quality.”
Statistical analysis
The pooled prevalence and 95% confidence interval (CI) 
of each CMR finding were estimated using a generalized 
Fig. 1 Flowchart of the literature review process
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linear mixed model. The heterogeneity between stud-
ies was assessed using chi-square-based Q statistics 
and  I2 statistics [31, 32], and significant heterogeneity 
was defined as a P-value of < 0.1 or an  I2 value of > 50%. 
Subgroup analysis of the prevalence of CMR findings 
was performed for the “athlete” versus (vs.) “non-ath-
lete” subgroups and the “normal cardiac enzyme level” 
vs. “undetermined cardiac enzyme level” subgroups. 
Meta-regression analysis was performed for major CMR 
parameters to investigate their contribution to a study’s 
heterogeneity, using the covariates “athlete” and “unde-
termined cardiac enzyme level.” Variables with P-values 
of < 0.2 in the univariable meta-regression analysis were 
included in the multivariable analysis. A P-value of < 0.05 
was considered to indicate a statistically significant dif-
ference in the multivariable analysis. Publication biases 
were drawn as funnel plots and evaluated using the Egger 
test [33]. The analysis was performed using R (version 
4.0.3; R Foundation for Statistical Computing, Vienna, 
Austria) with the “metafor” and “meta” packages [34, 35].
Results
Study characteristics
Following the literature search, 890 patients from 16 
studies were included in this meta-analysis [11–14, 16–
22, 28, 29, 36, 37]. Tables  1 and 2 summarize the study 
characteristics and CMR protocols of the included stud-
ies, respectively. A greater percentage of the included 
studies were conducted retrospectively (62.5%) at a sin-
gle institution (93.8%). Most studies (81.3%) obtained 
cine, parametric  mapping (native T1 and T2), and LGE 
sequences [11–14, 16–19, 21, 22, 28, 36, 37]. Similarly, 
nine studies obtained T2w sequences [11, 12, 16, 17, 20, 
21, 28, 29, 36], and one study obtained a non-contrast-
enhanced CMR without an LGE sequence [17].
Six of the 16 included studies enrolled only athletes as 
participants [16, 19, 21, 28, 36, 37], whereas there was no 
restriction on the occupation of study participants in the 
other 10 studies [11–18, 20, 29]. Eight studies had popu-
lations with normal cardiac enzyme levels [11, 12, 15, 
16, 19, 28, 29, 37]. Seven other studies had patients with 
undetermined cardiac enzyme levels [13, 14, 17, 18, 20–
22], and one study reported data for normal and undeter-
mined cardiac enzyme level subgroups [36].
Pooled prevalence of abnormal CMR findings
The pooled prevalence values of abnormal CMR find-
ings are summarized in Table  3 and Fig.  2. The overall 
prevalence of any abnormal CMR finding in recovered 
COVID-19 patients was 46.4% (95% CI 43.2%–49.7%) 
in 16 studies [11–22, 28, 29, 36, 37]. The pooled preva-
lence of a CMR diagnosis of myocarditis was 14.0% 
(95% CI 11.6%–16.8%) in 12 studies [11–14, 16, 19, 21, 
22, 28, 29, 36, 37]. The pooled prevalence of pericardial 
and myocardial LGE was 5.0% (95% CI 3.8%–6.7%) in 14 
studies [11–16, 18–21, 28, 29, 36, 37] and 20.7% (95% CI 
18.1%–23.5%) in 15 studies [11–16, 18–22, 28, 29, 36, 37], 
respectively. The pooled prevalence of total (pericardial 
or myocardial) LGE was 20.5% (95% CI 17.7%–23.6%) in 
13 studies [11–16, 19, 20, 22, 28, 29, 36, 37].
The pooled prevalence of an elevated native T1 was 
26.3% (95% CI 23.1%–29.8%) in 10 studies [11, 14, 16–19, 
21, 22, 28, 36] and that of a T2 abnormality (increased 
T2 value on the T2 map or abnormal SI on T2 weighted 
(T2w) imaging was 16.9% (95% CI 14.3%–19.8%) in 12 
studies [11–14, 16–19, 21, 22, 28, 36]. The pooled preva-
lence of a T2 abnormality without LGE was 4.0% (95% CI 
2.3%–6.7%) in eight studies [12, 13, 16, 19, 21, 22, 28, 36], 
and that of LGE without a T2 abnormality was 4.0% (95% 
CI 2.3%–7.0%) in seven studies [12, 16, 19, 21, 22, 28, 29]. 
The pooled prevalence of pericardial effusion was 15.7% 
(95% CI 13.2%–18.5%) in 11 studies [11–14, 16, 18, 19, 
21, 22, 28, 36], and that of ventricular systolic dysfunction 
on cine CMR was 4.7% (95% CI 3.3%–6.6%) in 10 studies 
[11, 13, 14, 16, 19, 21, 28, 29, 36, 37]. Significant hetero-
geneities among the included studies were observed for 
all parameters of abnormal findings  (I2 > 50%).
Prevalence of abnormal CMR findings relative to patient 
characteristics
The pooled prevalence values of abnormal CMR findings 
within subgroups are summarized in Table 3.
Non‑athletes vs. athletes
Of the 890 patients in 16 studies, 316 (35.5%) sub-
jects  were athletes [16, 19, 21, 28, 36, 37]. The pooled 
prevalence of abnormal CMR findings and a CMR diag-
nosis of myocarditis was higher in non-athletes than in 
athletes (62.5% vs. 17.1% and 23.9% vs. 2.5%, respec-
tively). Similarly, compared with athletes, non-athletes 
had a higher pooled prevalence of other CMR abnor-
malities, including myocardial LGE (28.8% vs. 6.7%), an 
elevated native T1 (39.8% vs. 4.4%), a T2 abnormality 
(22.9% vs. 4.4%), a T2 abnormality without LGE (12.9% 
vs. 1.6%), pericardial effusion (17.3% vs. 12.8%), and ven-
tricular systolic dysfunction (7.4% vs. 1.3%). In contrast, 
the pooled prevalence values were slightly higher in ath-
letes than in non-athletes for pericardial LGE (6.7% vs. 
4.1%) and were similar in both groups for myocardial 
LGE without T2 abnormality (4.1% vs. 3.8%). After sub-
group analysis, the heterogeneity of studies became insig-
nificant for abnormal CMR and ventricular dysfunction 
in both subgroups and the presence of myocardial LGE 
without T2 abnormality in the non-athlete subgroup (all, 
p > 0.1,  I2 < 50%).
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Fig. 2 Pooled prevalence of abnormal CMR findings in patients who recovered from COVID-19. a Pooled prevalence of total abnormal CMR 
findings. b Pooled prevalence of the diagnosis of myocarditis on CMR. c Pooled prevalence of pericardial late gadolinium enhancement (LGE). d 
Pooled prevalence of myocardial LGE. e Pooled prevalence of LGE (pericardial or myocardial). f Pooled prevalence of native T1 abnormality on the 
T1 map. g Pooled prevalence of T2 abnormality. h Pooled prevalence of LGE without T2 abnormality. i Pooled prevalence of T2 abnormality without 
LGE. j Pooled prevalence of pericardial effusion. k Pooled prevalence of ventricular systolic dysfunction. CMR, cardiovascular magnetic resonance; 
COVID-19, coronavirus disease 2019; LGE, late gadolinium enhancement
Normal cardiac enzyme level vs. undetermined cardiac 
enzyme level
Among the 890 patients in 16 studies, 474 (53.3%) from 
nine studies [11, 12, 15, 16, 19, 28, 29, 36, 37] had normal 
enzyme levels (e.g. troponin) and 406 (45.6%) from eight 
studies had undetermined cardiac enzyme levels [13, 14, 
17, 18, 20–22, 36]. The undetermined cardiac enzyme 
level subgroup exhibited a higher pooled prevalence than 
the normal cardiac enzyme level subgroup for abnormal 
CMR findings (59.4% vs. 35.9%), the presence of pericar-
dial (24.8% vs. 10.4%) or myocardial LGE (36.5% vs. 8.6%), 
an elevated native T1 value (35.7% vs. 1%), T2 abnormal-
ity (24.8% vs. 10.4%), and pericardial effusion (17% vs. 
5.2%). In contrast, the pooled prevalence values were 
higher in the normal cardiac enzyme level subgroup than 
in the undetermined cardiac enzyme level subgroup for a 
diagnosis of myocarditis on CMR (15.2% vs. 12.0%) and 
the presence of myocardial LGE without T2 abnormality 
(4.4% vs. 1.6%). After subgroup analysis, the heterogene-
ity between studies became insignificant for ventricular 
dysfunction in the undetermined enzyme level subgroup 
(p = 0.34,  I2 = 22%).
Meta-regression analysis results are summarized in 
Table  4. In the univariable meta-regression analyses, 
the athlete subgroup was significantly associated with 
heterogeneity for abnormal CMR findings, myocarditis 
diagnosis on CMR, myocardial LGE, and a T2 abnor-
mality (all, p < 0.2). In contrast, undetermined cardiac 
enzyme level was significantly associated with hetero-
geneity for abnormal CMR findings and the presence 
of myocardial LGE (all, p < 0.2). In the multivariable 
meta-regression analyses, being an athlete was a sig-
nificant independent factor associated with heteroge-
neity for abnormal CMR findings (p < 0.05). However, 
undetermined cardiac enzyme levels were not signifi-
cantly associated with heterogeneity in multivariable 
meta-regression analyses.
Quality of the studies
The quality assessments of the included studies are 
summarized in Additional file  1: Table  S1. Most stud-
ies were classified as “high quality” (87.5% of the studies 
received scores of 6 or 7, and 12.5% received a score of 
5).
Systematic review of the ECV, patterns of LGE, and cine 
findings
ECV findings
Six studies reported that ECV was significantly higher in 
recovered COVID-19 patients than in healthy controls 
[11, 12, 15, 16, 19, 37]. Huang et  al. showed that ECV 
was significantly higher in recovered COVID-19 patients 
who showed abnormal CMR findings than in controls 
(median ECV: 28.2% vs. 23.7%, p = 0.001) [12]. Eiros et al. 
reported that the prevalence of elevated ECV was 37.4% 
(52/139) in recovered COVID-19 patients [11]. Li et  al. 
reported that ECV was significantly elevated in patients 
recovered from moderate (median ECV, 29.7%) or severe 
COVID-19 (median ECV, 31.4%) relative to healthy con-
trols (median ECV 25%, p < 0.001) and that the preva-
lence of elevated ECV was 60% (24/60) in recovered 
COVID-19 patients [15]. Three studies on athlete par-
ticipants reported a relatively lower prevalence of abnor-
mal ECV (Rajpal et al.: 3.8%, 1/26; Clark et al.: 4.5%, 1/22; 
Malek et al.: 0%, 0/26) than two studies on non-athletes 
(Eiros et al.: 37.4%, Li et al.: 60%) [16, 19, 37].
Patterns of LGE, the involved segments of LGE, and T2 
abnormalities on CMR
A non-ischemic LGE pattern was the most frequent pat-
tern of myocardial LGE reported in 11 studies (87.9%, 
123/140, Table 2) [12–14, 16, 18–20, 22, 28, 29, 37]. Spe-
cifically, subepicardial, epicardial, and mid-wall LGE 
were the patterns reported in these studies. Frequently 
reported myocardial LGE locations in eight studies 
included the mid and basal inferior, septal, and lateral 
segments [14–17, 19, 20, 29, 37].
Two studies reported eight locations of T2 abnor-
malities in six patients [19, 28]. Similar to the LGE 
location, the mid-inferoseptum (37.5%, 3/8) and mid-
anteroseptum (25%, 2/8) were the most common loca-
tions reported in the study by Rajpal et al. [19]. A study 
by Clark et  al. on athletes reported that the T2 value 
was significantly higher in athletes who recovered from 
COVID-19 than healthy athlete controls (p = 0.02) [37].
Ventricular systolic dysfunction on cine sequence
Among the 16 included studies, six were excluded from 
the meta-analysis for ventricular dysfunction because the 
prevalence could not be extracted [12, 13, 15, 18, 20, 28]. 
(see figure on next page)
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Fig. 2 continued
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Four studies reported that significant RV dysfunction was 
observed in recovered COVID-19 patients [12, 17, 19, 
37]. Huang et  al. reported that the RV ejection fraction 
(RVEF) was significantly lower in recovered COVID-19 
patients with abnormal CMR findings than in healthy 
controls (RVEF 36.5% vs. 46.1%, p = 0.01). In contrast, 
the left ventricular (LV) ejection fraction (LVEF) was 
low in only one patient (3.9%, 1/26) with abnormal CMR 
findings [12]. Pan et  al. reported a decrease in RVEF in 
two patients (9.5%), and the mean RVEF was significantly 
Fig. 2 continued
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lower in recovered COVID-19 patients than in controls 
(p < 0.05). However, the mean LVEF was similar between 
recovered COVID-19 patients and controls [17].
LV or biventricular dysfunction in recovered COVID-
19 patients has been evaluated in previous studies [11, 
13, 18, 21]. Puntmann et al. measured and reported that 
the LVEF and RVEF were significantly lower in recovered 
COVID-19 patients than in matched controls (LVEF: 57% 
vs. 62%; RVEF: 54% vs. 59%) (all, p < 0.05) [18]. Malek 
et al. and Eiros et al. reported that the prevalence of LV 
systolic dysfunction in recovered COVID-19 patients was 
8% and 5%, respectively.
Malek et  al. reported that two athletes (8%) exhibited 
an enlarged LV with a slightly decreased LVEF, whereas 
RVEF was normal [16]. Although Eiros et  al. reported 
LV wall motion abnormalities in seven patients (5%, 
Fig. 2 continued
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7/139), data on RV function were not provided [11]. 
Although ventricular systolic function was normal, 
abnormal strain values were reported in two studies [15, 
20]. Li et  al. reported that global LV longitudinal strain 
was significantly lower in patients who recovered from 
moderate or severe COVID-19 than in healthy controls 
(moderate COVID-19 group: − 12.5%; severe COVID-
19 group: − 12.5%; healthy controls: − 15.4%; p = 0.002 
and p = 0.001, respectively) [15]. Wang et  al. reported 
that recovered COVID-19 patients with LGE had signifi-
cantly lower peak global circumferential strain values in 
the LV and RV and lower peak global longitudinal strain 
values in the RV than recovered COVID-19 patients with 
no LGE or healthy controls (both, p < 0.05) [20]. No cine 
abnormalities were reported in the populations studied 
by Vago et al., Ng et al. and Kotecha et al. [13, 14, 36].
Fig. 2 continued
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Publication bias
Funnel plots of the prevalence values of abnormal CMR 
findings, a diagnosis of myocarditis on CMR, myocar-
dial LGE, a T2 abnormality, and pericardial effusion are 
presented in Additional file 1: Fig. S1. All parameters had 
symmetric funnel plots without significant publication 
bias (p > 0.05), except for T2 abnormality without LGE 
(p = 0.04).
Fig. 2 continued
Table 4 Meta-regression analysis for prevalence of each CMR finding





Residual heterogeneity after 
multivariable meta-regression 
analysis
p-value I2 p-value I2
Abnormal CMR findings 92.8%
 Athlete group 0.002 93.4% 0.018
 Undetermined cardiac enzyme level group 0.061 94.6% 0.173
Diagnosis of myocarditis on CMR N/A
 Athlete group  < 0.001 90.6% N/A
 Undetermined cardiac enzyme level group 0.405 93.7% N/A
Presence of myocardial LGE 93.9%
 Athlete group 0.050 95.4% 0.206
 Undetermined cardiac enzyme level group 0.033 94.0% 0.138
T2 abnormality N/A
 Athlete group 0.035 97.2% N/A
 Undetermined cardiac enzyme level group 0.629 96.9% N/A
Pericardial effusion N/A
 Athlete group 0.753 93.8% N/A
 Undetermined cardiac enzyme level group 0.353 92.1% N/A
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Discussion
This meta-analysis revealed that nearly half of the 
patients exhibited one or more abnormal CMR findings 
after recovery from COVID-19. Athletes and patients 
in the normal cardiac enzyme level subgroups showed 
a lower prevalence of abnormal CMR findings than 
non-athletes and patients in the undetermined cardiac 
enzyme level subgroups. The most frequent abnormal 
CMR finding was the presence of an elevated native T1 
value on the T1 map (26.3%), followed by a presence of 
myocardial LGE (20.7%).
Non-invasive CMR is a valuable diagnostic tool to 
evaluate the presence and extent of myocardial injury in 
COVID-19 patients [9]. A previously published system-
atic review reported CMR findings for 199 COVID-19 
patients, including patients with myocarditis (40.2%), 
myopericarditis, stress-induced cardiomyopathy, and 
ischemia [10]. However, the studies included in this sys-
tematic review primarily conducted CMR during the 
active phase of COVID-19 [10]. Therefore, the data did 
not contribute to our understanding of whether myo-
cardial inflammation or scarring would be observed on 
CMR in recovered COVID-19 patients.
Patients with myocarditis may develop arrhythmia or 
heart failure after recovery due to residual myocardial 
fibrosis or scarring [7]. LGE with T2 abnormality on 
CMR suggests that myocardial edema is present and the 
myocarditis is in the acute inflammatory phase. Conse-
quently, the extent of LGE can diminish after recovery 
[38]. In contrast, LGE without a T2 abnormality after 
recovery from myocarditis indicates myocardial scarring 
or fibrosis and is associated with a poorer prognosis [9, 
39]. The prevalence of LGE in myocarditis patients other 
than COVID-19 dropped from 72 to 48% and that of a 
T2 abnormality decreased from 57 to 7% at 12  months 
follow-up in a previous study [38].
The time interval between a diagnosis of COVID-
19 and CMR varied among the studies included in this 
meta-analysis. Nevertheless, CMR was performed within 
22 weeks of COVID-19 diagnosis, a shorter interval than 
that reported in previous studies on non-COVID-19 
myocarditis [38]. The pooled prevalence of CMR findings 
of acute myocarditis in recovered COVID-19 patients 
diagnosed with myocarditis (14.0%), elevated native T1 
(26.3%), myocardial LGE (20.7%) and T2 abnormality 
(16.9%) was higher than that of myocardial LGE without 
T2 abnormality (4.0%), which indicates permanent myo-
cardial scarring and is associated with a poor prognosis. 
A mid-wall septal pattern of LGE, a poor prognostic fac-
tor in non-COVID-19 myocarditis, has been reported 
in several studies [14, 16, 20, 28]. These results suggest 
that active myocardial inflammation persists in the early 
phase of recovery from COVID-19. Therefore, the results 
of large-scale, ongoing studies (C-MORE, CISCO-19 and 
COVID-HEART) with long-term follow-up may address 
whether these findings will disappear or remain as per-
manent myocardial fibrosis [40–42].
Myocarditis in athletes can be critical because ath-
letes place themselves at a higher risk of sudden cardiac 
death or adverse cardiac events during strenuous exer-
cise [25]. Currently, the consensus among experts does 
not recommend routine CMR for evaluating whether 
to allow athletes who recovered from COVID-19 to 
return to play [43–46]. Typically, CMR is not a first-
line modality for evaluating patients with suspected 
myocardial injuries. Instead, CMR is performed after 
electrocardiography, cardiac biomarker analysis, or 
transthoracic echocardiography to provide a more 
advanced and comprehensive evaluation in patients 
with ongoing clinical concerns [43–46]. Although the 
prevalence of abnormal CMR findings was lower in 
athletes than in non-athletes in this meta-analysis, the 
prevalence of LGE without T2 abnormality was simi-
lar between the two groups. Moreover, the prevalence 
of pericardial LGE was higher in athletes than in non-
athletes. Therefore, long-term follow-up studies with 
larger numbers of participants (athletes) who recovered 
from COVID-19 are necessary to determine the signifi-
cance of LGE observed on CMR.
In this meta-analysis, we observed that patients with 
normal cardiac enzyme levels had less frequent CMR 
abnormalities than patients with unknown cardiac 
enzyme levels (59.4% vs. 35.9%). Although our meta-anal-
ysis could not include a subgroup analysis for patients 
with elevated cardiac enzymes, elevated troponin levels 
are well-established markers of myocardial injury. High 
troponin levels are associated with severe disease and a 
poor prognosis in COVID-19 patients [47, 48]. Elevated 
troponin levels in recovered COVID-19 patients suggests 
ongoing subclinical inflammation; however, it is uncer-
tain whether normal cardiac enzyme levels indicate an 
absence of myocardial scars. CMR may provide risk strat-
ification for patients who recovered from COVID-19.
Besides myocardial abnormality, ventricular systolic 
dysfunction and pericardial abnormalities have also 
been reported in recovered COVID-19 patients. RV 
systolic dysfunction is the most common cine abnor-
mality in recovered COVID-19 patients and is associ-
ated with increased pulmonary vascular resistance [49], 
acute respiratory distress syndrome, and poor outcomes 
in patients with COVID-19 [50]. Although the preva-
lence of functional abnormalities is low relative to those 
observed for other CMR parameters, studies clarifying 
the mechanism underlying the restoration of cardiac 
function in these patients are needed. This meta-anal-
ysis revealed that pericardial effusion was frequently 
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observed in recovered COVID-19 patients, whereas peri-
cardial LGE was relatively rare. Pericarditis, pericardial 
effusion, and cardiac tamponade have occasionally been 
reported during the active phase of COVID-19 [51, 52]; 
however, the underlying mechanisms remain unclear. 
Inadequate immune response to COVID-19 may lead to 
slower clearance of the virus from the peri-myocardium, 
development of pericarditis secondary to myocardial 
inflammation, or pericardial effusion caused by general-
ized COVID-19-related multi-systemic inflammatory 
syndrome [13, 18, 21]. The outcome of this evidence is 
unknown; however, our study findings would support 
further study.
Comprehensive and definitive cardiac imaging guide-
lines for recovered COVID-19 patients, especially the 
non-athlete population, are lacking. Future large-scale, 
long-term studies may reveal the clinical significance of 
abnormal CMR findings. Based on our study and future 
studies, appropriate surveillance guidelines for using 
CMR and other cardiac imaging modalities in recovered 
COVID-19 patients should be established.
Limitations
Our study has several limitations. First, the subgroup of 
patients with elevated cardiac enzyme levels could not be 
analyzed due to the small number of studies and patients. 
Second, an analysis of ventricular systolic dysfunction 
in the subgroup of patients with normal cardiac enzyme 
levels was not conducted due to the small number of 
patients with ventricular systolic dysfunction. Third, cer-
tain data necessary for subgroup analysis, such as the 
presence of cardiac symptoms or underlying cardiac dis-
ease, or abnormalities revealed on electrocardiography or 
echocardiography, could not be extracted. Lastly, CMR 
scans were performed within 22  weeks of COVID-19 
recovery, and longer-term studies are needed to deter-
mine the clinical significance of these findings.
Conclusions
Nearly half of those recovering from COVID-19 exhibit 
one or more abnormal CMR findings. The prevalence 
of abnormal CMR findings was lower in athletes and 
patients with normal cardiac enzyme levels than in non-
athletes and patients with undetermined cardiac enzyme 
levels. We propose that comprehensive surveillance with 
CMR could help stratify the risks of cardiovascular com-
plications in recovered COVID-19 patients.
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